By Sougato Das, President and COO, LSN
As 2025 progresses, China’s biotech and pharmaceutical sectors are not just growing—they’re reshaping the global industry landscape. With skyrocketing innovation, bold regulatory reform, and a deepening rivalry with the U.S., Chinese biotech firms are asserting their global presence at unprecedented speed. The GSK / Hengrui Pharma deal, involving a major collaboration potentially worth up to $12.5 billion, is the latest example. The deal focuses on developing up to a dozen drug candidates, primarily in respiratory diseases, immunology, infection, and oncology. GSK will pay Hengrui an upfront fee of $500 million, with the potential for significant milestone payments and royalties if the collaboration is successful. China will continue to play a major role in the worldwide biopharma ecosystem as…
China Emerges as a Global Drug Development Powerhouse
- Record Licensing Activity: China-to-West drug licensing hit a record $41.5 billion in 2024, a staggering 66% jump from the previous year. Nearly 30% of global innovative drug assets now trace their origin to China.
- Biotech Licensing Leadership: In 2024, 42% of all global biotech licensing deals over $50 million involved Chinese firms—up from 22% in 2023.
Drug Discovery Is Going East
- Rapid Shift in Molecule Sourcing: One in three externally sourced molecules by global biopharma firms now comes from China—a dramatic rise from virtually none in 2019. Chinese biotech firms are lauded for their speed, efficiency, and low-cost synthesis of new compounds, positioning them as preferred partners for drug discovery.
Clinical Trials and Regulatory Momentum increases in China
- China’s Clinical Surge: In 2023, nearly 28% of global clinical trial sponsorships originated from China—up from just 4% a decade ago. Registrations alone rose by 26% last year.
- Faster to Market: Thanks to reforms by China’s National Medical Products Administration (NMPA), investigational new drugs can now be approved for human testing in just 60 working days.
- FDA Recognition: Chinese trials are increasingly qualifying for FDA priority pathways, challenging the traditional dominance of U.S.-based clinical development.
China is at the Cutting Edge of Gene Editing
- CRISPR Leadership: Chinese startups like YolTech (in vivo CRISPR therapy) and Huidagene (brain-targeted CRISPR trials) are leading in next-gen gene editing.
- Global Recognition: According to Goldman Sachs, China is at the forefront of CRISPR and CAR-T research.
Tensions and Regulatory Hurdles deepen with the US
- Geopolitical Pressure: Proposed U.S. legislation—the BIOSECURE Act—would prohibit drugmakers with federal contracts from using Chinese firms like WuXi AppTec and WuXi Biologics after 2032. This could disrupt global supply chains and complicate R&D strategies for U.S. companies.
- Scientific Chilling Effect: Fears of increased scrutiny are causing some Chinese and Chinese-American researchers to avoid applying for NIH grants, impacting U.S.-China scientific collaboration.
- Investment Headwinds: Despite innovation, venture capital investment in Chinese biotech has declined due to geopolitical uncertainty.
Cross-Border Deals Multiply
- Western Biopharma Engagement: U.S. and European firms are actively pursuing licensing and partnership deals with Chinese biotechs—particularly in ADC and bispecific antibody platforms, expanding beyond oncology.
- Investor Sentiment Splits: Some U.S. investors advocate for protectionist strategies, while others see China’s rise as an opportunity for strategic alignment and access to novel therapies.
What Does All This Means for the Industry>
China is no longer simply a “fast follower” in biotech. It’s now an originator of breakthrough science, shaping the future of global drug development, even as geopolitical tensions threaten to redraw the map of international collaboration.
As global biopharma leaders and investors reassess their strategies, one thing is clear: ignoring China’s biotech ascent is no longer an option.
Next Phase Newsletter 